Back to top

Image: Bigstock

Pacira Pharmaceuticals, Inc.

Read MoreHide Full Article

Pacira's top line mainly comprises of contribution from its marketed product Exparel. Its efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel with their sales and medical education teams. Pacira’s agreement with China-based Nuance for the development and commercialization of Exparel in China is also a positive. Shares of Pacira have outperformed the industry so far this year. However, the company is heavily dependent on Exparel for growth, which is concerning.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pacira BioSciences, Inc. (PCRX) - free report >>